The preclinical and clinical results of a subset of CD34+ cells will be presented. The cells were used in three different clinical trials: Patients with liver failure; patients with acute total ischemic circulation anterior stroke and patients with diabetes complicated by renal transplant. Safety and efficacy aspects of the studies will be discussed and also a new technique to increase efficacy of stem cells using small activating RNA.

Biography

Nagy Habib is a Lead Clinician for the Liver and Pancreatic Unit at Imperial College Healthcare NHS Trust and Academic Head of the Department of Surgery at the Hammersmith Hospital Campus of Imperial College London. He is a Translational Researcher who pioneered the first clinical trial in the use of plasmid and adenovirus for the treatment of liver cancer as well as the use of plasmid gene therapy in hydrodynamic gene delivery. As a Clinical Scientist he has conducted and published translational research in liver tumours on oncogene, tumour suppressor gene, epigenetic modification, gene therapy, stem cell therapy and small activating RNA. He was the inventor and was co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA) and interventional radiology (Habib™ VesOpen). He holds a gold award from the Advisory Committee for Clinical Excellence and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. He was awarded Honorary Professorships by universities in China, Bulgaria, Greece and Russia. In November 2012 he was awarded Takreem Laureate for his contribution to technology and science.

nagy.habib@imperial.ac.uk

Notes: